News

CrossBridge Bio Secures Major Funding for Next-Gen Cancer Treatments

CrossBridge Bio Secures Major Funding for Next-Gen Cancer Treatments

CrossBridge Bio Secures Significant Financing for Cancer Therapies

CrossBridge Bio, a pioneering biotechnology company specializing in dual-payload antibody-drug conjugates (ADCs), has successfully closed a funding round totaling $10 million. This funding is spearheaded by reputable investors, including TMC Venture Fund and CE-Ventures. With participation from significant entities like Portal Innovations, Alexandria Venture Investments, and Linden Lake Labs, this financing round marks a critical step in the advancement of innovative cancer therapies.

Innovative Approach to Cancer Treatment

The foundation of CrossBridge Bio's technology stems from groundbreaking research conducted by distinguished scientists, Dr. Kyoji Tsuchikama and Dr. Zhiqiang An, affiliated with UTHealth Houston. Their research has paved the way for a unique dual-payload ADC platform that effectively combines established and novel antibodies. This approach incorporates diverse mechanisms of action, making it possible to create an extensive array of ADC programs. These programs promise to deliver specific molecular characteristics, distinct pharmacological actions, and favorable safety profiles across various cancer types.

Focus on CBB-120 Development

With the newly acquired seed capital, CrossBridge Bio aims to expedite the development of its lead candidate, CBB-120. This prospective best-in-class TROP-2 dual-payload ADC targets solid tumors, thereby significantly contributing to the existing ADC therapies. Furthermore, the funds will support the enhancement of the company's proprietary linker technology, which is essential for dual-payload applications. This technology optimization aims to boost the safety and efficacy of both current and future drug candidates in the pipeline.

Leadership and Strategic Growth

The financing round also leads to notable changes within the leadership structure. William McKeon, the President and CEO of the Texas Medical Center (TMC), along with Damir Illich, Ph.D., the Manager of Life Sciences at CE-Ventures, will join CrossBridge Bio’s board of directors. Their expertise in healthcare and life sciences will be invaluable in fostering the company's strategic growth and navigating challenges in the biotechnology landscape.

Positive Impact on Patients

Michael Torres, Ph.D., CEO of CrossBridge Bio, expressed the company’s optimism regarding the support from experienced investors. He emphasized the goal of utilizing the dual-payload ADC technology to produce synergistic therapeutic effects while maintaining a high level of stability. This ensures that the therapeutic agent is released specifically within targeted cancer cells, maximizing treatment efficacy and minimizing side effects commonly associated with existing therapies.

McKeon highlighted the potential global impact of CrossBridge Bio's innovations, stating that the advancements in dual-payload ADCs could significantly change the lives of cancer patients worldwide. Illich echoed this sentiment, expressing excitement over the prospects that lie ahead for CBB-120 and the company’s broader pipeline of therapies.

A Bright Future for CrossBridge Bio

CrossBridge Bio stands at the forefront of a transformative era in cancer treatment. The focus on stable, dual-payload ADC therapeutics offers new hope for tackling various solid tumor types. CBB-120 is poised to make a meaningful impact in the therapeutic landscape, addressing critical challenges such as tumor heterogeneity and resistance commonly faced in cancer therapies today.

About CrossBridge Bio

CrossBridge Bio is redefining the approach to antibody-drug conjugate (ADC) therapeutics. The company is harnessing cutting-edge technology from the labs of Dr. Kyoji Tsuchikama and Dr. Zhiqiang An, focusing on innovative linker technology that enables enhanced stability and payload versatility. This strategic focus aims to expand their portfolio of dual-payload ADC programs targeting solid tumors, particularly through the promising candidate CBB-120. Established during the TMC Innovation’s Accelerator for Cancer Therapeutics program, CrossBridge Bio is headquartered in Houston, TX, and is at the leading edge of next-generation cancer therapies.

Frequently Asked Questions

What is CrossBridge Bio known for?

CrossBridge Bio is known for developing dual-payload antibody-drug conjugates (ADCs) for targeted cancer therapies.

How much funding did CrossBridge Bio secure?

The company secured $10 million in seed financing to support its research and development efforts.

What is the purpose of the new funding?

The funding will accelerate the development of CBB-120 and enhance the company's ADC platform technologies.

Who are the new board members at CrossBridge Bio?

William McKeon and Damir Illich, Ph.D., are joining the board, bringing their expertise in healthcare and life sciences.

What is CBB-120?

CBB-120 is a lead candidate ADC developed by CrossBridge Bio targeting solid tumors, aiming to improve cancer treatment outcomes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 60

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 19

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 24

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 139

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 11

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 150

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 94

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 31

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 343

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

BitGo Faces Securities Fraud Suit Amid Investor Losses

Updated Category News Views 69

BitGo's Legal Woes: A Deep Dive into the Allegations A lawsuit can shake up a company's foundations, and BitGo Holdings, Inc. (NYSE: BTGO) is feeling the heat right now. The focus of this busy investor morning isn’t some penny stock drama; we're talking about players in the digital asset game accused of pulling the wool over investors' eyes. Slap on those reading...

Continue Reading
Investors Alert: Deadline Approaches in Match Group Lawsuit

Updated Category News Views 141

Important Deadline Approaching for Match Group Investors Recently, there has been a notable reminder for investors concerning a class action lawsuit involving Match Group, Inc. (NASDAQ: MTCH). The law firm Glancy Prongay & Murray LLP has highlighted that all individuals who purchased shares in Match Group during the specified period should be aware of the upcoming...

Continue Reading
Leadership Transition at Coloplast A/S: New Era Begins

Updated Category News Views 937

Coloplast A/S Announces Leadership Change In a significant shift for Coloplast A/S, CEO Kristian Villumsen has officially stepped down. Today marks the start of a new chapter as the Board of Directors mobilizes Lars Rasmussen to serve as interim CEO while the search for a permanent replacement is conducted. Strategic Shift for the Future This change comes at an opportune...

Continue Reading
Johnson & Johnson's Strong Q3 Results Amid Market Declines

Updated Category News Views 109

Market Overview On a day marked by declining values, U.S. stocks experienced a noticeable downturn. The Nasdaq Composite index saw a drop of around 150 points, indicating a challenging market environment. As trading progressed, the Dow Jones Industrial Average slipped slightly, and the S&P 500 also followed suit, showing varied performance across sectors. Sector...

Continue Reading
Moroccanoil Expands Product Line at Ulta Beauty Nationwide

Updated Category News Views 204

Moroccanoil Expands Product Line at Ulta Beauty Nationwide Moroccanoil is thrilled to announce an exciting partnership with Ulta Beauty, the premier beauty retailer in the nation. This significant expansion reaffirms Moroccanoil's commitment to delivering high-quality beauty products to a wider audience while honoring its legacy rooted in the salon community. Launching at...

Continue Reading